New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015 by Krieken, J.H.J.M. van
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/153495
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
REVIEW OF THE LITERATURE
New developments in the pathology of malignant lymphoma:
a review of literature published from January 2015 to April 2015
J. Han van Krieken1
Published online: 17 June 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Introduction
The amount of data we need to digest becomes almost too
large: data from large sequencing experiments and also data
from the increasing number of scientist around the world.
Looking at the series of articles, I had to go through for this
review I sometimes feel overwhelmed. Nevertheless, I have
tried to make my personal selection again.
Biology of lymphoma
The possibilities of generating large amounts of data are enor-
mous indeed. The challenge is to generate meaningful infor-
mation from the results of large sequencing approaches. A
nice example is the approach by Cimmino et al. [1]. They
focus on ‘ten-eleven translocation 1’ (TET1) which is an im-
portant regulator of 5-hydroxymethylcytosine (5hmC) in em-
bryonic stem cells, and the loss of 5hmC in many tumours
suggests a critical role for the maintenance of this epigenetic
modification. In mice, they found that deletion of TET1 pro-
moted the development of B cell non-Hodgkin lymphoma (B-
NHL). TET1 appeared to be required for maintenance of the
normal abundance and distribution of 5hmC, which prevented
hypermethylation of DNA, and for regulation of the B cell
lineage and of genes encoding molecules involved in chromo-
some maintenance and DNA repair. Then, they reasoned that
based on these data, TET1-deficient B cell lymphomas might
have specific mutations. Whole-exome sequencing (WES) in-
deed confirmed that these mutations were frequently found in
B-NHL in which TET1 was hypermethylated and transcrip-
tionally silenced. They conclude that TET1 acts as a tumour
suppressor of B-NHL. A more inventory approach was cho-
sen by Braggio et al. [2] who performed a genome-wide anal-
ysis of 19 primary diffuse large B cell lymphomas (DLBCLs)
of the central nervous system (CNS) by array comparative
genomic hybridization (CGH) and WES. They found biallelic
inactivation of TOX and PRKCD, which is not present in
systemic DLBCL. In addition, they found a high prevalence
of MYD88 mutations (79 %) and CDKN2A biallelic loss
(60 %) and alterations in many other genes of the NF-κB
pathway, but these are not unique for DLBCL of the CNS.
Overall NF-κB pathways were altered in >90 % of these
cases. These findings indicate that primary DLBCL of the
CNS genetically differs from DLBCL from other sites, but
that there are also commonly affected pathways. A similar
approach (using large amounts of data from multiple ap-
proaches on a rare tumour) was taken by Lee et al. [3] for 34
cases of extranodal NK/T cell lymphoma nasal type (ENKL).
They performed multiple types of next-generation sequenc-
ing, including WES (9 cancer tissues and 4 cancer cell lines),
targeted sequencing (21 cancer tissues) and RNA sequencing
(3 cancer tissues and 4 cancer cell lines). Mutations were
found most frequently in three genes, STAT3, BCOR and
MLL2 (which were present in nine, seven and six cancer sam-
ples, respectively), whereas there were only two cases of Ja-
nus kinase 3 (JAK3) mutation. In total, JAK/STAT pathway-
and histone modification-related genes accounted for 55 and
38 % of the cancer samples, respectively, and their involve-
ment in ENKL pathogenesis was also supported by gene ex-
pression analysis. They conclude that they found several novel
driver genes of ENKL, which may be future therapeutic tar-
gets in this disease. Finally, with the present approach to
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sequencing, also more data regarding so-called pseudogenes
become available and it has become clear that these may have
more important roles than previously thought. Karreth et al.
[4] show that mice engineered to overexpress either the full-
lengthmurineB-Raf pseudogeneBraf-rs1 or its pseudo ‘CDS’
or ‘3′ UTR’ develop an aggressive malignancy resembling
human DLBCL. They show that Braf-rs1 and its human
ortholog, BRAFP1, elicit their oncogenic activity, at least in
part, as competitive endogenous RNAs (ceRNAs) that elevate
BRAF expression and MAPK activation in vitro and in vivo.
Furthermore, they show that transcriptional or genomic aber-
rations of BRAFP1 occur frequently in multiple human can-
cers, including B cell lymphomas. These data indicate that
indeed also pseudogenes are relevant players in the develop-
ment of B cell lymphomas.
All in all, these studies show that we seem to be only at the
beginning of understanding the complexity of the molecular
basis of cancer and specifically lymphomas.
B cell lymphomas
One of the important drivers of B cell lymphomas, espe-
cially low-grade types, is the signalling though the antigen
receptor. Many studies have addressed the composition of
the immunoglobulin genes to get a better grip on the un-
derstanding of its role. Berget et al. [5] investigated the V
family usage in 99 cases of low-grade follicular lymphoma
(FL) and correlated the results with outcome. They found
preferred usage of immunoglobulin heavy variable 3
(IGHV3) (58 %), and those patients with IGHV5 or more
than one V family usage had a significantly worse out-
come. In contrast with chronic lymphatic leukaemia
(CLL), there was no difference in the prognosis between
patients who had unmutated versus mutated sequences.
These results indicate that the specific antigen receptor is
probably quite relevant, but that more detailed understand-
ing of the antigen (if any) involved is urgently needed. An
example of a much more detailed approach is the work by
Green et al. [6], who analyzed purified FL cells and iden-
tified additionally recurrently mutated genes and con-
firmed mutations of one or more chromatin modifier genes
in almost all cases. They defined the hierarchy of somatic
mutations arising during tumour evolution by analyzing
the phylogenetic relationship of somatic mutations across
the coding genomes of 59 sequentially acquired biopsies
from 22 patients. CREBBP mutations were most signifi-
cantly enriched within the earliest progenitor cell. These
mutations were associated with a signature of decreased
antigen presentation characterized by reduced transcript
and protein abundance of MHC class II on tumour B cells,
in line with the role of CREBBP in promoting class II
transactivator (CIITA)-dependent transcriptional activation
of these genes. CREBBP mutant B cells stimulated less
proliferation of T cells in vitro compared with wild-type
B cells from the same tumour. Transcriptional signatures of
tumour-infiltrating T cells were indicative of reduced pro-
liferation, and this corresponded to decreased frequencies
of tumour-infiltrating CD4 helper T cells and CD8 memory
cytotoxic T cells. These observations therefore implicate
CREBBP mutation as an early event in FL evolution that
contributes to immune evasion via decreased antigen
presentation.
Further proof of the role of antigens as a driver of B cell
lymphoma, in this case mantle cell lymphoma (MCL), comes
from Xochelli et al. [7]. They found the AID full-length tran-
script and the most frequent splice variants (AID-ΔE4a,
AID-ΔE) in 128 (96 %), 96 (72 %) and 130 cases (98 %) of
MCL, respectively. Higher AID full-length transcript levels
were significantly associated with lack of somatic
hypermutation within the IGHV genes. Although most cases
exhibited low levels of intraclonal diversification, analysis of
the mutational activity revealed precise targeting of somatic
hypermutation indicative of an active, ongoing interaction
with antigen(s). These findings indeed strongly allude to an-
tigen involvement in the natural history of MCL.
Pan et al. [8] hypothesized that epigenetic changes are im-
portant in the progression of DLBCL. They compared the
genome-wide methylation profile of relapsed DLBCL with
that of the original tumour and found a ‘relapse-associated
methylation signature’ that included the transforming growth
factor beta (TGF-β) receptor pathway. They also observed
decreased intra-tumour methylation heterogeneity from diag-
nosis to relapsed tumour samples. Relapse-free patients dis-
play lower intra-tumour methylation heterogeneity at diagno-
sis compared with relapsed patients in an independent valida-
tion cohort. A better understanding of the underlying mecha-
nism may therefore be of help to get a better idea on tumour
progression in DLBCL.
A more targeted approach was taken by Dubois et al. [9]
with a focus on enhancer of zeste homolog 2 (EZH2), of
which recurrent somatic heterozygous gain-of-function
mutations of EZH2 have been identified in DLBCL. Since
EZH2 inhibitors are being tested in phase 1 and 2 clinical
trials, they want to develop a biomarker that predicts effect.
By immunohistochemistry, they determined the methyla-
tion profiles of the DLBCL from 82 patients as well as
the mutational profiles of EZH2 in the lymphomas of 32
patients with DLBCL with a next-generation sequencing
(NGS) approach (panel of 34 genes involved in lympho-
magenesis). They developed a score based on H3K27me2
and H3K27me3 expression that distinguished patients with
wild-type (WT) EZH2 and patients with EZH2 Y641 mu-
tation. NGS analysis revealed a subclonal EZH2 mutation
pattern in EZH2 mutant patients with WT-like immunohis-
tochemistry (IHC) methylation profiles, while associated
mutations capable of upregulating EZH2 were detected in
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WT EZH2 patients with mutant-like IHC methylation pro-
files. The next step is going to show that this score is really
predicting therapeutic response of EZH inhibitors.
T cell lymphoma
Cresenzo et al. [10] focus with their genomic evaluation on
anaplastic lymphoma kinase (ALK)-negative (ALK−) ana-
plastic large cell lymphoma (ALCL). They identified activat-
ing mutations of JAK1 and/or STAT3 genes in approximately
20 % of 155 ALK− ALCLs and demonstrated that 38 % of
systemic ALK− ALCLs displayed double lesions. Recurrent
chimeras combining a transcription factor (NFkB2 orNCOR2)
with a tyrosine kinase (ROS1 or TYK2) were also discovered
in WT JAK1/STAT3 ALK− ALCL. All these aberrations lead
to the constitutive activation of the JAK/STAT3 pathway,
which was proved to be oncogenic. Finally, they showed that
JAK/STAT3 pathway inhibition impairs cell growth in vitro
and in vivo, and this is therefore a rationale for a new treat-
ment approach.
Epidemiology of lymphoma
Normally, we deal with the diagnosis of lymphomas and have
good ideas on the treatments that will follow our diagnosis as
well as the resulting outcomes. We even are aware of second-
ary cancers, which is especially a burden in survivors of
Hodgkin lymphoma (HL). I think it is also relevant to have
an idea of less visible consequences. Glimelius et al. [11]
analyzed data from a population-based registry from Sweden
on almost 2000 HL patients, with clinical data of more than
1000 of them, and compared these with those of a matched
cohort. The data include patients diagnosed between 1992 and
2009 with follow-up until 2013. The results indicate that HL
survivors have a 30–50 % increase in the risk of work loss,
even when this was adjusted for secondary effects like cardio-
vascular disease and secondary cancers. This underpins the
major effect a cancer diagnosis has for patients. This is an area
that may be subject of overdiagnosis, and thus, major unnec-
essary impact is in paediatric cases, especially paediatric nodal
marginal zone B cell lymphoma (NMZL). Excellent work
from Kluin et al. [12] showed that the spectrum of paediatric
marginal zone hyperplasia to lymphoma may have a common
cause—a Haemophilus influenzae-driven immune response.
In six children with polyclonal marginal zone hyperplasia
and four adolescents with clonal NMZL, they looked for the
presence of H. influenzae. In all patients with hyperplasia,
they detected H. influenzae (either direct culture or highly
sensitive PCR), whereas this was lacking in the lymphoma
cases. In only 1/28 control samples, they detected the micro-
organism, in very low quantity. Of note, in the hyperplasia
cases, they detected areas with light chain restriction
(confirmed by flow cytometry). Since several H. influenzae
strains are known to interact with the constant part of IgD on
human B cells, leading to their polyclonal proliferation and
activation, the authors speculate that in vivo stimulation of
IgD+ marginal zone B cells by this bacterium may be impli-
cated in this particular lymphadenopathy. The results of
course indicate to be very careful with the diagnosis of paedi-
atric NMZL; the methods they used to detect H. influenzae
require quite some expertise and preferably the availability of
frozen tissue and is therefore not feasible for most
laboratories.
There are other microorganisms involved in lymphomas
like the Epstein-Barr virus (EBV), hepatitis C and
Helicobacter pylori (amongst others). According to Tognon
et al. [13], we need to add simian virus 40 (SV40) to the list. In
serum samples from NHL-affected patients (n=150) along
with controls represented by patients with other cancers (n=
142) and healthy subjects (n=300), they found antibodies
against SV40 in about 40 % of the NHL patients, 20 % in
other cancer patients and 15 % in healthy individuals. Of
course, such an association does not directly proof that
SV40 plays a role in the lymphoma development, but is inter-
esting enough to further study its role.
To have an idea on the outcome of rare lymphomas, there is
a need for data from large registries. Xing et al. [14] analyzed
clinicopathologic features for 107 patients (diagnosed be-
tween 1985 and 2012) with splenic MZL (SMZL) which ac-
counts for less than 2% of all NHL cases. Themedian age was
67 years (range 30–88), with 40 % male, almost all stage IV
and with splenomegaly, bone marrow involvement and pe-
ripheral blood involvement (87 %). As initial treatment, 52
underwent splenectomy (10 with chemotherapy), 38 chemo-
therapy alone (21 chemoimmunotherapy containing rituxi-
mab, 1 rituximab alone) and 2 antivirals for hepatitis C, and
15 were observed only. The 10-year overall survival for first-
line splenectomy versus chemotherapy was 61 and 42 %, re-
spectively. The 10-year failure-free survival after first-line
splenectomy versus chemotherapy was 39 and 14 %.
Amongst the 38 patients who received first-line chemothera-
py, the addition of rituximab did not result in increased sur-
vival. Fifteen patients transformed to aggressive lymphoma
with median time to transformation of 3.5 years (range
6 months to 12 years), and the 10-year transformation rate
was 18 %. The authors conclude that splenectomy remains a
reasonable treatment for patients with SMZL. Parry et al. [15]
try to find prognostic markers for this lymphoma type. In 175
cases, they found recurrent mutations in TP53 (16 %), KLF2
(12 %), NOTCH2 (10 %), TNFAIP3 (7 %), MLL2 (11 %),
MYD88 (7%) and ARID1A (6%).KLF2mutations were early,
clonal events, enriched in patients with del(7q) and IGHV1-
2*04 B cell receptor immunoglobulins, and were associated
with a short median time to first treatment. In multivariate
analysis, mutations in NOTCH2 and 100 % germline IGHV
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gene identity were independent markers of short time to first
treatment, while TP53mutations were an independent marker
of short overall survival. They conclude that they have dem-
onstrated that NOTCH2 and TP53 gene mutations are inde-
pendent markers of reduced treatment-free and overall surviv-
al in SMZL. How this translates to altered clinical decision-
making remains unclear.
Litvinov et al. [16] investigated the geographic clus-
tering of cutaneous T cell lymphoma (CTCL), which is
always quite risky in rare tumours. Using region, zip
code, age, sex and ethnicity, the authors analyzed the
demographic data of 1047 patients from Texas from
2000 through 2012 and another set of 1990 patients
who were recorded between 1996 and 2010. There
was geographic clustering of patients in three communi-
ties in which CTCL incidence rates were 5 to 20 times
higher than the expected population rate. The authors
conclude that their data indicate the existence of yet
unknown external causes/triggers for this rare malignan-
cy. Although the data are relatively large, still such
conclusions have to be drawn very cautiously, since
familial clustering, enhanced awareness and chance
may underlie such clustering as well.
Defining entities
B cell lymphomas
A mutation in the MYD88 gene is present in over 90 % of
lymphoplasmacytic lymphomas (LPLs) and since this en-
tity is sometimes difficult to separate from MZ Martinez-
Lopez et al. [17] investigated lymphoma samples from 19
patients with LPL, 88 patients with SMZL, 8 patients with
nodal (N)MZL and 21 patients with extranodal (EN)MZL.
Of note, upon review and integrating mutational, histolog-
ic and clinical data, five cases were reclassified as LPL,
reiterating the fact that this diagnosis is not always
straightforward. After reclassification, MYD88 L265P
was detected in 13/86 (15 %) SMZL and in 19/24 LPL
(79 %) cases. The mutation was absent from NMZL and
ENMZL cases. A strong correlation was found between
the presence of an IgM monoclonal paraproteinaemia and
the MYD88 L265P mutation. SMZL cases positive for
MYD88 L265P were also associated with monoclonal
IgM paraproteinaemia (4/13 cases), although with less se-
rum paraproteinaemia. They also had a higher frequency
of plasmacytic differentiation (9/13) but with no correla-
tion between the presence of mutation and of light chain-
restricted plasma cells in tissue. The authors conclude that
demonstration of the MYD88 L265 mutation is a valuable
tool for the diagnosis of LPL, although some SMZL cases
carrying the mutation do not fulfil the diagnostic criteria
for LPL. The MYD88-negative LPL cases, nevertheless,
may pose a challenge to separate from NMZL with
plasmacytic differentiation.
Morita et al. [18] addressed the issue of so-called in
situ FL. As I discussed in previous reviews of the litera-
ture, this lesion is rare in unselected patient groups and
seems to have little clinical consequences when found as
an isolated finding. The approach of Morita et al. was the
other way around: they looked for patients with FL who
had a previous abdominal cancer with lymph node resec-
tion and found 4 such patients from a total of 150 patients
with FL. All four had in situ FL in the previously resected
lymph nodes. The time from lymphadenectomy to the
diagnosis of FL was 23–120 months. They conclude that
although the rate for development of FL in individuals
with in situ FL is low in prospective studies, their data
indicate that follow-up studies for a longer period are
necessary. However, I would certainly not advocate to
look for this lesion with bcl2 staining in lymph nodes
from abdominal cancer patients, since it would result in
unnecessary worry of a second malignancy in these cancer
patients while it still seems that the chance that they have
clinical relevant disease is low and there is no place for
early treatment.
Some FL cases are CD5 positive, but the meaning of
this aberrant expression is not clear. Li et al. [19] collect-
ed 88 such cases (53 men and 35 women; median age,
60 years; range, 31–86). The lymphoma was diagnosed
relatively often at an extranodal (EN) site (initially in
lymph nodes in 66 and EN sites in 22 patients). The pres-
ence of t(14;18)(q32;q21)/IGH-BCL2 or another BCL2
translocation was relatively low in 28/44 (64 %) cases.
Clinical features also differed with CD5-negative FL; with
a median follow-up of 55 months, 15 patients died which
is rather high; this fits with the relatively high Internation-
al Prognostic Index, and commonly development of
DLBCL (38/88). They conclude that CD5 expression in
FL is associated with an adverse outcome; however, it
remains questionable whether all these cases really repre-
sent FL or may be other lymphoma types with extensive
follicular colonization.
Primary DLBCL of the testis is a lymphoma with spe-
cific clinical and pathological features. Twa et al. [20]
performed bacterial artificial chromosome capture se-
quencing on three such cases and found novel CIITA,
FOXP1 and PDL rearrangements involving IGHG4,
FLJ45248, RFX3, SMARCA2 and SNX29. Immunohisto-
chemistry showed an association between PDL rearrange-
ments and increased protein expression. Using fluores-
cence in situ hybridization (FISH) in a larger series of
testicular DLBCL, CIITA (8/82; 10 %) and FOXP1
(5/74; 7 %) rearrangements appeared to be recurrent. The-
se data suggest that immune-checkpoint inhibitor therapy
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might be a promising intervention for this rare lymphoma
type that develops in an immune-privileged site.
T cell lymphomas
ALK-positive and ALK-negative ALCL share morpholog-
ical features but differ in prognosis and, obviously, ALK
expression as a result from the t(2;5) translocation.
Steinhilber et al. [21] compared the microRNA (miRNA)
expression between these two types. Their NGS approach
identified 106 significantly differentially expressed
miRNAs. The top significantly differentially expressed
miRNAs included five upregulated miRNAs: miR-340,
miR-203, miR-135b, miR-182 and miR-183 and seven
downregulated miRNAs: miR-196b, miR-155, miR-146a,
miR-424, miR-503, miR-424* and miR-542-3p. The miR-
17-92 cluster was also upregulated in ALK+ cells. Addi-
tionally, they identified a signature of three miRNAs sig-
nificantly regulated by the transcription factor C/EBPβ,
which is specifically overexpressed in ALK+ ALCL, in-
cluding the miR-181 family. Of interest, miR-181a, which
regulates T cell differentiation and modulates T cell recep-
tor (TCR) signalling strength, was significantly downreg-
ulated in ALK+ ALCL cases. These data reveal a miRNA
signature linking ALK+ ALCL to a deregulated immune
response and may reflect the abnormal TCR antigen ex-
pression known in ALK+ ALCL. Merkel et al. [22] take
this work further. They also found that ALK-positive
ALCL, in contrast to ALK-negative ALCL, displays low
miR-155 expression, and discovered that this is due to
miR-155 promoter methylation, but there was no direct
effect of the ALK kinase on miR-155 levels. Induced
overexpression of miR-155 in ALK-positive ALCL cell
lines resulted in reduced levels of C/EBPβ and SOCS1.
In murine engraftment models of ALK− ALCL, anti-miR-
155 mimics are able to reduce tumour growth and in-
crease levels of cleaved caspase-3 and SOCS1 resulting
in suppression of STAT3 signalling. These data suggest
that miR-155 can act as a tumour driver in ALK-
negative ALCL, and blocking miR-155 could be thera-
peutically relevant. The data also indicate that ALK-
positive ALCL and ALK-negative ALCL are biologically
really different entities.
Cutaneous lymphomas
Cutaneous follicle centre cell lymphoma (CFCL) is
regarded as a completely different disease than FL, al-
though FL may be manifested in the skin. Several studies
have shown that CFCL lacks a bcl2 rearrangement in con-
trast to FL. Pham-Ledard et al. [23] confirm this knowl-
edge by analyzing 47 CFCL, 4 of which carry a bcl2 break
by FISH, and 6 FL presenting with skin involvement, 3 of
which have a bcl2 break. Since some of the CFCL with a
bcl2 break had systemic disease and poor prognosis, one
may doubt the diagnosis in these cases.
Pitfalls in lymphoma diagnosis
The role of EBV in lymphoproliferation in patients with var-
ious forms of immune suppression is well known, but it re-
mains a challenge when to investigate for EBVand what to do
with a positive result. In patients with inflammatory bowel
disease (IBD), several case reports indicate an increased risk
in EBV-positive lymphoproliferations, but it is unclear how
aggressive this disease is. Nissen et al. [24] collected biopsies
from 58 patients with IBD who had been tested for the pres-
ence of EBV, 28 of which were positive. The presence of EBV
was correlated with an atypical infiltrate, which was present in
more than 50 % of the EBV-positive cases and only one of the
EBV-negative cases. Two EBV-positive patients had overt
lymphoma, and eight had a monomorphic infiltrate. After re-
ducing immune suppression, the morphology returned to nor-
mal, although one of the two lymphoma patients had in addi-
tion chemotherapy. No patient died from the lymphoprolifer-
ation, but four EBV-positive patients underwent colectomy
due to severe complaints. These data indicate that the presence
of EBV-positive lymphoproliferation in IBD can be suspected
based on morphology, but that it is less aggressive compared
to other immune-suppressed situations.
Prognostic factors in lymphoma
Also this time, there is a small selection of articles that deal
with prognostication in NHL. I chose those articles that have
high-quality data, including a discovery and a confirmation
cohort and well-defined relevant patient selection.
In FL, Kridel et al. [25] applied IHC for CD68 and CD163
to two large tissue microarrays (TMAs): one with samples
from 186 patients from the BC Cancer Agency (BCCA) and
the other with 395 samples from the PRIMA trial patients.
Both groups had been treated with rituximab, but within dif-
ferent chemotherapy regimes. Macrophage infiltration was
assessed using image analysis, and an increased CD163-
positive pixel count was predictive of an adverse outcome in
the BCCA dataset (5-year progression-free survival 38 versus
72 % in the training cohort and 29 versus 61 % in the valida-
tion cohort). However, in the PRIMA trial, an increased
CD163 pixel count was associated with favourable outcome
(60 versus 44 % in the training cohort and 55 versus 37 % in
the validation cohort). These data clearly indicate the impor-
tance to correlate a prognostic factor to well-defined patient
groups, but also that it is difficult to introduce such a marker in
clinical practice.
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miRNA profiling is very well feasible on paraffin-
embedded tissue specimens, and therefore, many studies are
done using this technique. A good example is the work by
Husby et al. [26] who performed genome-wide miRNA mi-
croarray profiling of 74 diagnostic MCL samples from the
Nordic MCL2 trial (screening cohort). Prognostic miRNAs
were validated in diagnostic MCL samples from 94 patients
of the independent Nordic MCL3 trial (validation cohort).
Three miRNAs (miR-18b, miR-92a and miR-378d) were sig-
nificantly differentially expressed in patients who died of
MCL in both cohorts. miR-18b was superior to miR-92a and
miR-378d in predicting high risk. Transfection of two MCL
cell lines with miR-18b decreased their proliferation rate with-
out inducing apoptosis, suggesting that miR-18b may render
MCL cells resistant to chemotherapy by decelerating cell pro-
liferation. Based on these results, they generated a new bio-
logical MCL International Prognostic Index (MIPI-B)-miR
prognosticator, which improved the identification of high-
risk patients with regard to cause-specific, overall and
progression-free survival.
The lymphoma on which most prognostic work is
done is DLBCL. Shepshelovich et al. [27] performed
miRNA profiling but had only 83 samples, predefined
in favourable and poor prognosis, with a validation set
of only 13 cases. The approach resulted in significant
differences, but the findings did not add to the standard
prognostic indicators. Knudsen et al. [28] took a more
thorough approach. They developed a miRNA response
predictor in DLBCL based on the measured growth in-
hibition of 60 human cancer cell lines (NCI60) in the
presence of doxorubicin, cyclophosphamide, vincristine
and etoposide as well as the baseline microRNA expres-
sion of the 60 cell lines. This response predictor
consisting of 20 microRNAs was blindly validated in a
cohort of 116 de novo DLBCL patients treated with R-
CHOP or R-CHOEP as first-line treatment. The predicted
sensitivity based on diagnostic FFPE samples matched
the clinical response. When the International Prognostic
Index (IPI) was included in the prediction analysis, the
separation between responders and non-responders im-
proved. The predictions were almost the same when di-
agnostic biopsies were used as when relapse biopsies
were used. These preliminary findings warrant testing
in a larger cohort of relapse patients to confirm whether
the miRNA-based predictor can select the optimal
second-line treatment and increase survival.
MYC status is a relevant issue in DLBCL, but the impact
varies amongst the subtype of lymphoma and the type of
MYC alteration. Caponetti et al. [29] investigated the sig-
nificance ofMYC, BCL2 and BCL6 gene abnormalities in a
cohort of 205 DLBCL patients studied by conventional
and/or fluorescence in situ hybridization cytogenetic anal-
ysis. One hundred seventy-two cases (84 %) were
classified as MYC−, 17 (8 %) were MYC+/BCL2−/
BCL6−, and 16 (8 %) were double/triple-hit lymphomas
(i.e. MYC+/BCL2+, MYC+/BCL6+ or MYC+/BCL2+/
BCL6+). They found a significant difference in event-free
survival amongst the three groups, with the double/triple-
hit group having the worst outcome. Somewhat surprising,
patients who were MYC+, but BCL2− and BCL6−, do not
have a worse outcome when compared to those who are
MYC− which is in contrast with existing data in the litera-
ture. Li et al. [30] looked for MYC protein expression in
primary mediastinal DLBCL, although these cases rarely
have a genetic event that includes a MYC alteration. They
found variable MYC protein expression by IHC in 30
(94 %) of 32 cases including 10 cases with high MYC
IHC expression of at least 30 % positive nuclei. FISH
analyses for MYC rearrangement on these 10 cases were
negative. Review of clinical data of a subset (!) of cases
with high- and low-MYC IHC expression showed no dif-
ferences in clinical outcome. These results are somewhat
difficult to interpret, but actually, the numbers are too low
to draw meaningful conclusions. Even the work of Wang
et al. [31], which has findings that are contradictory to
these results, lacks sufficient power, although they study
135 cases of DLBCL. They analyzed the differences be-
tween genetic double-hit lymphomas and those defined on
protein expression. They determined in their cohort in
whom MYC/8q24 and BCL2/t(14;18)(q32;q21) statuses
were assessed by FISH at diagnosis of MYC and BCL2
expression by immunohistochemistry. A total of 54
(40 %) cases were positive for both MYC and BCL2,
supporting a diagnosis of double-hit lymphoma, which is
a quite high number compared to those of the literature.
Amongst them, 19 (35 %) had MYC rearrangement, 12
(22 %) had multiple copies of MYC, 19 had no MYC ab-
normalities, and in 4 cases, FISH analysis failed. BCL2
abnormalities were present in 28/54 (52 %) cases (20
rearranged and 8 multiple copies). MYC rearrangement
correlated with a significantly worse overall survival,
whereas BCL2 genetic status did not correlate with surviv-
al. They conclude that MYC and BCL2 expression by im-
munohistochemistry correlates with gene status by FISH,
but that immunohistochemistry is neither specific nor ade-
quately sensitive to be used as a surrogate for MYC and
BCL2 gene status using any cut-off level.
Enteropathy-associated T cell lymphoma (EATL) has a
particularly poor prognosis, and the International Prog-
nostic Index and the prognostic index for peripheral T cell
lymphoma have limited predictive value for outcome. De
Baaij et al. [32] performed a retrospective multicenter
study, based on 92 patients. They were able to distinguish
three risk groups: a high-risk group, characterized by the
presence of B symptoms (median overall survival of
2 months); an intermediate-risk group, comprising
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patients without B symptoms and an IPI score ≥2
(7 months); and a low-risk group, representing patients
without B symptoms and an IPI score of 0–1 (34 months).
They conclude that their new validated prognostic model
(EPI) accurately predicts survival outcome in EATL and
may be used for patient selection for new therapeutic
strategies and evaluation of clinical trials.
Ancillary techniques
Technological development is one of the drivers of modern
pathology. Newmethods therefore need to be evaluated all the
time to see whether they can improve standard pathology.
Liang et al. [33] retrospectively analyzed EBV status in 232
DLBCL patients using EBV-encoded small RNA (EBER) in
situ hybridization (ISH) and EBV DNA analysis in whole
blood. EBER was positive in 24 (10 %) patients, and EBV
DNAwas positive in 18 (10 %) patients; the two analyses had
more than 90 % concordance. EBV-positive patients as deter-
mined by both techniques had worse overall survival than
those without EBV positivity. The additional value of blood
testing above tissue testing lies in the following: the transfor-
mation from positive to negative after cycle 3 with chemother-
apy had the most capacity to distinguish a superior from an
inferior outcome. These findings suggest that EBV DNA in
whole blood has good concordance with EBER ISH and that it
may be a good biomarker for monitoring the disease.
Although clonality testing is already a high level, high-
quality test, the development of next-generation sequencing
may have its impact in this area of pathology, too.
Appenzeller et al. [34] developed a next-generation sequenc-
ing approach on the ion torrent personal genome machine to
characterize the immunoglobulin heavy gene V-D-J rear-
rangements. The method was applied to two diagnostic tissue
samples, including formalin-fixed and paraffin-embedded tis-
sue, of two patients with iatrogenic immunodeficiency-
associated Epstein-Barr virus lymphoproliferative disorder,
with ulcerative colitis as underlying disease. The immuno-
globulin rearrangement sequences obtained by next-
generation sequencing revealed undoubtedly clonally related
lesions in two tissue biopsies that were taken over time in the
first patient, which is concordant with disseminated lympho-
ma. The other patient showed two clonally unrelated lesions,
which is incompatible with clonal dissemination. This infor-
mation was not inferred from evaluation of the heavy and
light chain rearrangements by fragment analysis, which is
currently the gold standard. This study nicely demonstrates
the diagnostic application of next-generation sequencing of
immunoglobulin rearrangement assessment in pathology for
clinical decision-making in patients with several simulta-
neous or subsequent lymphoproliferations. Another study
using a next-generation sequencing approach investigated a
different potential use. Kurtz et al. [35] prospectively evalu-
ated its utility in 311 blood and 105 tumour samples from 75
patients with DLBCL, comparing the cellular (circulating leu-
kocytes) and acellular (plasma cell-free DNA) compartments
of peripheral blood. The results were related to clinical out-
comes and 18FDG PET/CT (n=173). Clonal immunoglobu-
lin rearrangements were detected in 83 % of patients with
adequate tumour samples to enable subsequent monitoring
in peripheral blood (which is lower than when the complete
Biomed set is used). Molecular disease measured from plas-
ma, as compared to circulating leukocytes, was more abun-
dant and more correlated with radiographic disease burden.
Prior to treatment, molecular disease was detected in the plas-
ma of 82 % of patients compared to 71 % in circulating cells.
However, molecular disease was detected significantly more
frequently in the plasma at time of relapse (100 vs. 30 %).
Detection of molecular disease in the plasma often preceded
PET/CT detection of relapse in patients initially achieving
remission. This method, therefore, is promising, as confirmed
by Roschewski et al. [36] who performed similar work. Clon-
al products were identified in pretreatment specimens from
126 patients who were followed up for a median of 11 years.
Interim monitoring of circulating tumour DNA at the end of
two treatment cycles in 108 patients showed a 5-year time to
progression of about 40 % in patients with detectable circu-
lating tumour DNA and 80 % in those without detectable
circulating tumour DNA. So, also this study indicates that
surveillance of circulating tumour DNA identifies patients at
risk of recurrence before clinical evidence of disease.
Already more than 10-year DLBCL is subdivided in-
to germinal centre B cell-like and activated B cell-like
subtypes. Still, these lymphomas are difficult to differ-
entiate in routine diagnosis, impeding the use of this
subtyping in clinical decision-making. Mareschal et al.
[37] therefore developed a simple and rapid classifier
based on a reverse transcriptase multiplex ligation-
dependent probe amplification assay and 14 gene signa-
tures. Compared with the Affymetrix U133+2 gold
standard, all 46 samples of a validation cohort classified
using both techniques were attributed to the expected
subtype. Similarly, 93 % of the 55 samples of a second
independent series characterized with a mid-throughput
gene expression profiling method were classified cor-
rectly. The developed assay was sensitive enough to
obtain reliable results from formalin-fixed, paraffin-
embedded samples and flexible enough to include prog-
nostic factors such as MYC/BCL2 co-expression. Final-
ly, in a series of 135 patients, both overall and
progression-free survival differences between the two
subtypes were confirmed. As the authors conclude, be-
cause the multiplex ligation-dependent probe amplifica-
tion method is already in use and requires only common
instruments and reagents, it could easily be applied to
J Hematopathol (2015) 8:71–79 77
clinical trial patient stratification to help in treatment
decisions.
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